Comprehensive cervical cancer screening by multiplexed HPV and biomarker mRNA detection using the Quantigene 2.0 platform

Speaker

Abstract

Background and aim:
Multiplexing of biomarker panels by microsphere-based technologies are robust and cost-effective methods. The QuantiGene™ Plex Assay (ThermoFisher Scientific) platform quantitates mRNA expression from crude lysates discriminating up to 80 target sequences. We aim at using expression analyses fo Human Papillomavirus (HPV) oncogenes and cellular biomarkers corresponding to cervical dysplasia progression for screening and diagnostic molecular assays. Currently used DNA-based HPV tests are highly sensitive for infection but have low specificity for true disease. This is especially problematic in LMIC like in Africa where HPV prevalence is high, no screening approaches exist, and healthcare systems are overburdened.

Methods:
A 40-plex QuantiGene™ assay was designed to quantify mRNA expression of the E7 oncogene of 18 high-risk HPV genotypes, cellular housekeeping genes for normalization, and 18 well established cellular biomarkers like proliferation markers, tumor suppressors, cancer stem cell transcription factors, and invasive tumor markers. Initially, the lysis procedure, sensitivity and specificity of the target sequences were tested in a pilot assay for feasibility with established cervical cancer cell lines. The suitability of the target panel and the assay procedure was tested on 1400 consecutive prospectively collected clinical samples. By logistic regression and ROC analyses marker sub-panels and cut offs were determined identifying and discriminating the different dysplastic stages and cervical cancer. Costs and workload were compared to a qRT-PCR-based method. The assay was used in two cervical cancer screening studies and compared to standard screening methods.

Results:
Feasibility of the assay was investigated by using established cervical cancer cell lines showing that HPV E7 and cellular biomarker expression was sufficiently sensitive detecting less than 40 cells. Most informative
biomarkers were identified by logistic regression. Characteristic marker panels for the dysplastic stages of cervical intraepithelial neoplasia (CIN)2+, CIN3+, and invasive cervical carcinoma were identified. High-grade dysplasia was detected in clinical smear samples with an accuracy of 90%. The comparison to qRT-PCR showed an acceptable correlation of results with remarkable lower costs and efforts for QuantiGene procedures. Using this assay in screening studies in Ethiopia and Germany resulted in much higher specificity for the detection of true dysplasia than the current standard of care. Importantly, work up of samples is simple (no nucleic acid purification and amplification), robust and especially adequate for
low-tech labs as found in LMIC.

Conclusion:
mRNA quantification by multiplexed bead-based technology is feasible in a cost effective way, simple and robust. Additionally, it presents an attractive means for IVD development for assay systems in cervical cancer screening and research.


Show Resources
You May Also Like
APR 07, 2020 8:00 AM PDT
C.E. CREDITS
APR 07, 2020 8:00 AM PDT
DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
MAY 08, 2020 10:00 AM PDT
C.E. CREDITS
MAY 08, 2020 10:00 AM PDT
DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
AUG 18, 2020 10:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
C.E. CREDITS
AUG 18, 2020 10:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
DATE: August 18, 2020 TIME: 10:00am PT Get deeper understanding of gene expression patterns by using assays that retain spatial organization at single cell resolution! Come learn about the n...
JUN 23, 2020 10:00 AM PDT
C.E. CREDITS
JUN 23, 2020 10:00 AM PDT
DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
FEB 25, 2020 9:00 AM PST
C.E. CREDITS
FEB 25, 2020 9:00 AM PST
Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
MAR 03, 2020 9:00 AM JST
C.E. CREDITS
MAR 03, 2020 9:00 AM JST
DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
Loading Comments...
Show Resources